CYP2C19 status and risk of major adverse cardiovascular events in peripheral artery disease: Insights from the EUCLID Trial

Authors

J. Antonio Gutierrez, Duke Clinical Research Institute
Gretchen M. Heizer, Duke Clinical Research Institute
W. Schuyler Jones, Duke Clinical Research Institute
Frank W. Rockhold, Duke Clinical Research Institute
Kenneth W. Mahaffey, Stanford University School of Medicine
F. Gerry R. Fowkes, Edinburgh Medical School
Jeffrey S. Berger, NYU Grossman School of Medicine
Iris Baumgartner, University Hospital Bern
Peter Held, Göteborgs Universitet
Brian G. Katona, AstraZeneca
Lars Norgren, Örebro Universitet
Juuso I. Blomster, Turun Yliopistollinen Keskussairaala
William R. Hiatt, University of Colorado School of Medicine
Manesh R. Patel, Duke Clinical Research Institute

Document Type

Letter to the Editor

Publication Date

11-1-2020

Journal

American Heart Journal

Volume

229

DOI

10.1016/j.ahj.2020.07.017

APA Citation

Gutierrez, J., Heizer, G., Jones, W., Rockhold, F., Mahaffey, K., Fowkes, F., Berger, J., Baumgartner, I., Held, P., Katona, B., Norgren, L., Blomster, J., Hiatt, W., & Patel, M. (2020). CYP2C19 status and risk of major adverse cardiovascular events in peripheral artery disease: Insights from the EUCLID Trial. American Heart Journal, 229 (). http://dx.doi.org/10.1016/j.ahj.2020.07.017